The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:09 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #22. Retrophin Manchester Pharmaceuticals

Acquirer: Retrophin (RTRX)
Acquiree: Manchester Pharmaceuticals
Details: Retrophin, Inc. (NASDAQ:RTRX) today announced that it has signed an agreement to acquire Manchester Pharmaceuticals LLC, a privately-held specialty pharmaceutical company that focuses on treatments for rare diseases. Under the terms of the agreement, Retrophin will pay a total of $62.5 million, including an upfront payment of $29.5 million, plus royalties based on product sales. The transaction is expected to close by March 1, 2014.

Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co.'s commercialized products include Chenodal (chenodiol tablets) for the treatment of radiolucent stones in well-opacifying gallbladders in patients; Cholbam (cholic acid capsules), a treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC (tiopronin), a treatment for cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Open the RTRX Page at The Online Investor »

Company Name: 
Travere Therapeutics Inc
Drugs & Pharmaceuticals

Open the RTRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree RTRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.75 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
RTRX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 22 of 83 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.